Albumin human
- Generic Name
- Albumin human
- Brand Names
- Albuked, Albuminex, Alburex, Alburx, Albutein, Flexbumin, Hizentra, Human Albumin Grifols, Kedbumin, Octalbin, Plasbumin, Plasmanate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9048-46-8
- Unique Ingredient Identifier
- ZIF514RVZR
- Background
Human serum albumin is the primary protein present in human blood plasma. The main function of albumin is to maintain the oncotic pressure of blood . It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). Albumin represents approximately 50% of the total protein co...
- Indication
Albuminex solution is indicated for adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass .
- Associated Conditions
- Acute Pyelonephritis(APN), Burns, Hemolytic Disease of the Newborn, Hypoalbuminemia, Hypoproteinemia, Hypovolaemia, Shock, Hypovolemic, Acute fulminant liver failure, Central volume depletion, Post-operative albumin loss
- Associated Therapies
- -
PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Democritus University of Thrace
- Target Recruit Count
- 250
- Registration Number
- NCT06630923
- Locations
- 🇬🇷
DUThrace Cardiology Department, Alexandroupolis, Evros, Greece
Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Protgen Ltd
- Target Recruit Count
- 388
- Registration Number
- NCT06553456
- Locations
- 🇨🇳
Shenzhen Protgen Ltd, Guangdong, Shenzhen, China
Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT06548477
- Locations
- 🇶🇦
Hamad General Hospital, Doha, Qatar
Effect of Early Administration of Albumin 20% Versus Crystalloid
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Egymedicalpedia
- Target Recruit Count
- 46
- Registration Number
- NCT06370078
- Locations
- 🇪🇬
Assuit University hospitals, Assiut, Egypt
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).
- Conditions
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 90
- Registration Number
- NCT05895136
- Locations
- 🇫🇷
Hôpital Beaujon, Clichy, France
🇪🇸Hospital Universitari Vall d'Hebron-VHIR, Barcelona, Spain
🇮🇹IRCSS Azienda Ospedaliero Universitaria di Bologna Policlinico di Sant'Orsola, Bologna, Emilia Romagna, Italy
Phase II/III of Recombinant Human Serum Albumin
- Conditions
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Protgen Ltd
- Target Recruit Count
- 92
- Registration Number
- NCT05858853
- Locations
- 🇨🇳
Shenzhen Protgen Ltd, Guangdong, Shenzhen, China
Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Albimmune SL
- Registration Number
- NCT05645887
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Protgen Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT05249374
- Locations
- 🇨🇳
Shenzheng Protgen Ltd, Guangdong, Shenzheng, China
Recombinant Human Serum Albumin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Protgen Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT05179265
- Locations
- 🇨🇳
Shenzheng Protgen Ltd, Guangdong, Shenzheng, China
Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Aleksander Krag
- Target Recruit Count
- 240
- Registration Number
- NCT05056220
- Locations
- 🇭🇺
Debreceni Egyetem, Debrecen, Hungary
🇳🇱Academisch Ziekenhuis Leiden, Leiden, Netherlands
🇳🇱Alrijne Ziekenhuis Leiden, Leiderdorp, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.